On December 15, 2021 Targovax ASA (OSE: TRVX) a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, reported that the Research Council of Norway has awarded Targovax a NOK 9.8m research grant towards product and clinical development for the TG mutant KRAS cancer vaccine program (Press release, Targovax, DEC 15, 2021, View Source [SID1234597216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Research Council of Norway has awarded the grant within the category "Innovation Project for the Industrial Sector".

Project title: "Development of targeted therapies for mutant RAS cancers"
Awarded by: The Research Council of Norway
Granted amount: 9.8 MNOK
Time frame: 2022-2025

Dr. Erik Digman Wiklund, CEO of Targovax, commented: "We are very grateful to be awarded this substantial and prestigious grant by the Research Council of Norway, which is a strong endorsement of the underlying science and broad potential of our mutant RAS program. These funds will enable continued clinical development of our TG vaccine candidates, as well as support important immunological characterization and product development".